Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Blood (2024) 144 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2024-209692

Published: 2024

Journal Articles

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Rebecca Svanberg Teglgaard, Rudi Agius, Caspar da Cunha-Bang, Tereza Faitova, Christian Brieghel, Hans Jakob Hartling, Hanne Vibeke Marquart, Robert Schou Pedersen, Christian Bjørn Poulsen, Mark-David Levin, Fransien De Boer, Koen de Heer, Rikke Kragh Lauridsen, Joanne Reekie, Anders Österborg, Jeanette Lundin, Magdalena Kättström, Sisse Rye Ostrowski, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 4609.

https://doi.org/10.1182/blood-2024-204985

Published: 2024

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Blood (2024) 144 (Supplement 1): 4626.

https://doi.org/10.1182/blood-2024-204852

Published: 2024

Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2024-207452

Published: 2024

Journal Articles

Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia

Emelie Curovic Rotbain, Mikkel Werling, Casper Møller Frederiksen, Christian Bjørn Poulsen, Martin Hutchings, Caspar Da Cunha-Bang, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2024-203172

Published: 2024

Journal Articles

Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab

Andreas Katsimigas, Lone Bredo Pedersen, Thure Haunstrup, Thor Hoeyer, Rikke Olsen, Michael Boe Møller, Emelie Curovic Rotbain, Caspar Da Cunha-Bang, Carsten Utoft Niemann, Christian Brieghel

Blood (2024) 144 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2024-203046

Published: 2024

Journal Articles

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Christian Brieghel, Julie Dubois, Ida Kappel Buhl, Kazem Nasserinejad, Dennis De Rooij, Karl Nyrén, Hoa T Tran, Sabina Kersting, Mattias Mattsson, Juha Ranti, Rogier Mous, Gerrit Jan Veldhuis, Caspar da Cunha-Bang, Mark-David Levin, Valtteri Wirta, Richard Rosenquist, Arnon P. Kater, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 586.

https://doi.org/10.1182/blood-2024-204532

Published: 2024

Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2024) 144 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2024-198917

Published: 2024

Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood (2024) 143 (25): 2588–2598.

https://doi.org/10.1182/blood.2023022564

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Gut Microbiome Links to Disease Stage and Immune Microenvironment in Patients with Chronic Lymphocytic Leukemia

Tereza Faitova, Caspar Da Cunha-Bang, Hans Jakob Hartling, Jakob Thaning Bay, Hanne Vibeke Marquart, Arnon P. Kater, Mark-David Levin, Sabina Kersting, Carsten Utoft Niemann, Rebecka Svanberg

Blood (2023) 142 (Supplement 1): 6515.

https://doi.org/10.1182/blood-2023-186158

Published: 2023

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Blood (2022) 140 (Supplement 1): 839–841.

https://doi.org/10.1182/blood-2022-163775

Published: 2022

Journal Articles

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Carsten U. Niemann, Caspar da Cunha-Bang, Marie Helleberg, Sisse R. Ostrowski, Christian Brieghel

Blood (2022) 140 (5): 445–450.

https://doi.org/10.1182/blood.2022016147

Published: 2022

Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 72.

https://doi.org/10.1182/blood-2021-147729

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2021-147790

Published: 2021

NARROW

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia

Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Gut Microbiome Links to Disease Stage and Immune Microenvironment in Patients with Chronic Lymphocytic Leukemia

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only